Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
It is aimed to investigate the responses of Fatty Acid Binding Protein 4 (FABP4), which has been discovered as a novel biomarker of obesity and metabolic diseases, to regular exercise training.
The aim of this study is to investigate the effects of high-intensity interval training (HIIT) on cardiometabolic risk factors, body composition, and plasma FABP4 levels in sedentary obese adults.
Fatty acid binding proteins are intracellular proteins involved in the transport of fatty acids and are particularly associated with lipolytic activity. These proteins constitute a group of molecules that regulate intracellular lipid responses and are linked to metabolic and inflammatory pathways.
Studies have shown that FABP4 is associated with hypertension, insulin resistance, obesity, and stroke.
Inhibition of FABP4 synthesis has emerged as a promising strategy for the treatment of obesity-related conditions, particularly insulin resistance and diabetes, and it is emphasized that exercise models to suppress FABP4 should be further investigated.
The aim of this study is to investigate the effects of high-intensity interval training (HIIT) on cardiometabolic risk factors, body composition, and plasma FABP4 levels in sedentary obese adults.
Hypotheses:
H01: HIIT has no effect on cardiometabolic risk factors in sedentary obese adults.
H02: HIIT has no effect on body composition in sedentary obese adults. H03: HIIT has no effect on plasma FABP4 levels in sedentary obese adults.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Exercise Group | Experimental | High-Intensity Interval Training (HIIT) 1-minute interval, 1-minute active recovery 5-minute warm-up, 3-minute cool-down at 60% of peak heart rate. Weeks 1-2: Intensity at 85% of peak heart rate during work, active recovery at 60% of peak heart rate, 4 sets of 1-minute work. Weeks 2-7: Intensity at 90% of peak heart rate during work, active recovery at 60% of peak heart rate, 6 sets of 1-minute work. Weeks 8-12: Intensity at 90% of peak heart rate during work, active recovery at 60% of peak heart rate, 8 sets of 1-minute work. |
|
| Control Group | No Intervention | No intervention will be applied to the control group. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Exercise | Other | The exercises will be applied only to the intervention group for 12 weeks and will be progressively intensified every 4 weeks. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Fatty acid-bling protein 4 | The Human FABP4 (Fatty Acid Binding Protein 4, Adipocyte) ELISA Kit/96T/Feiyuebio will be used to evaluate fatty acid-binding proteins in the biological samples collected from the participants. | Baseline, week 6 and week 12 |
| Complete Blood Count | used to evaluate overall health and detect a wide range of disorders, including anemia, infection, and many other diseases. | Baseline, week 6 and week 12 |
| Hemoglobin A1c (HbA1c) | used to measure the average blood glucose levels over the past 2 to 3 months; commonly used in the diagnosis and management of diabetes. | Baseline, week 6 and week 12 |
| Hematocrit (HCT) | sed to measure the proportion of red blood cells in the blood; helps evaluate conditions such as anemia, dehydration, and other blood disorders. | Baseline, week 6 and week 12 |
| Low-Density Lipoprotein | used to measure the level of "bad" cholesterol in the blood; high levels are associated with an increased risk of cardiovascular disease. | Baseline, week 6 and week 12 |
| High-Density Lipoprotein | Used to quantify the concentration of high-density lipoprotein (HDL) cholesterol in the bloodstream; elevated levels of HDL are inversely correlated with the risk of cardiovascular diseases, suggesting a protective effect on heart health. | Baseline, week 6 and week 12 |
| Triglycerides |
| Measure | Description | Time Frame |
|---|---|---|
| Physical Activity Level Assessment | The International Physical Activity Questionnaire Short Form will be used. A validity and reliability study has been conducted in Turkish, with test-retest reliability determined to be r=0.69. This form is self-administered and consists of seven questions assessing physical activity levels over the 'last seven days.' It provides information on time spent sitting, walking, engaging in moderate-intensity activities, and vigorous-intensity activities. The score is calculated by multiplying the minutes, days, and MET values. For calculations, 8 MET is used for vigorous physical activity, 4 MET for moderate-intensity activity, and 3.3 MET for walking. Since the scale is openly accessible, no usage permission is required. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| YAŞAM DİREL, MSc | Contact | 0090 392 6303939 | yasamdirel001@gmail.com | |
| Mehtap MALKOÇ, Professor. | Contact | 0090 392 6303939 | mehtap.malkoc@emu.edu.tr |
| Name | Affiliation | Role |
|---|---|---|
| YAŞAM DİREL, MSc | Eastern Meditterean university | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Eastern Mediterranean University | Recruiting | Famagusta | 99450 | Cyprus |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D015444 | Exercise |
| ID | Term |
|---|---|
| D009043 | Motor Activity |
| D009068 | Movement |
| D009142 | Musculoskeletal Physiological Phenomena |
| D055687 | Musculoskeletal and Neural Physiological Phenomena |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
used to measure the concentration of triglycerides (a type of fat) in the blood; elevated levels are associated with an increased risk of cardiovascular disease, metabolic syndrome, and other health conditions. |
| Baseline, week 6 and week 12 |
| Fasting Blood Glucose (FBG) | used to measure the concentration of glucose in the blood after an overnight fast; elevated levels may indicate impaired glucose metabolism or diabetes mellitus. | Baseline, week 6 and week 12 |
| Total Cholesterol | used to measure the overall concentration of cholesterol in the blood, including low-density lipoprotein (LDL), high-density lipoprotein (HDL), and very-low-density lipoprotein (VLDL); elevated levels are associated with an increased risk of cardiovascular diseases. | Baseline, week 6 and week 12 |
| Baseline, week 6 and week 12 |
| Physical activity level |
| Baseline, week 6 and week 12 |
| Assessment of Aerobic Capacity and Exercise Intensity - used to measure an individual's maximal oxygen uptake (VO2max) and determine the intensity of exercise | The Bruce Treadmill Test protocol will be used to determine aerobic capacity and exercise intensity. Developed by Robert A. Bruce, the Bruce Treadmill Test protocol is widely used today for non-invasive estimation of VO2max. The incline and speed are regularly increased to reach the maximum level that an individual can achieve. The test consists of 9 stages. Prior to the test, participants will receive the necessary information, and their resting blood pressure, heart rate, and oxygen saturation will be measured. At the end of each stage, an ECG measurement will be taken in addition to these measurements, and at the end of the test, all measurements will be repeated. The peak heart rate obtained at the end of the test will be considered the maximal heart rate. Additionally, the peak heart rate obtained will be used to determine the intensity of the exercise protocols. | Baseline, week 6 and week 12 |
| Anthropometric Measurements | Height (m) will be assessed by tape | Baseline, week 6 and week 12 |
| Antropometric Measurement | Body weight (kg) will be assessed using a Body Fat Analyzer. | Baseline, week 6 and week 12 |
| Antropometric Measurement | body mass indeks (kg/m²) will be calculated | Baseline, week 6 and week 12 |